Glycosylated nanoparticle-based PfCSP vaccine confers long-lasting antibody responses and sterile protection in mouse malaria model.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
07 Apr 2023
07 Apr 2023
Historique:
received:
25
12
2022
accepted:
23
03
2023
medline:
8
4
2023
entrez:
7
4
2023
pubmed:
8
4
2023
Statut:
epublish
Résumé
The development of an effective and durable vaccine remains a central goal in the fight against malaria. Circumsporozoite protein (CSP) is the major surface protein of sporozoites and the target of the only licensed Plasmodium falciparum (Pf) malaria vaccine, RTS,S/AS01. However, vaccine efficacy is low and short-lived, highlighting the need for a second-generation vaccine with superior efficacy and durability. Here, we report a Helicobacter pylori apoferritin-based nanoparticle immunogen that elicits strong B cell responses against PfCSP epitopes that are targeted by the most potent human monoclonal antibodies. Glycan engineering of the scaffold and fusion of an exogenous T cell epitope enhanced the anti-PfCSP B cell response eliciting strong, long-lived and protective humoral immunity in mice. Our study highlights the power of rational vaccine design to generate a highly efficacious second-generation anti-infective malaria vaccine candidate and provides the basis for its further development.
Identifiants
pubmed: 37029167
doi: 10.1038/s41541-023-00653-7
pii: 10.1038/s41541-023-00653-7
pmc: PMC10080175
doi:
Types de publication
Journal Article
Langues
eng
Pagination
52Subventions
Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : OPP1179906
Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : OPP1159947
Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : INV001759
Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : INV010271
Organisme : Bill and Melinda Gates Foundation (Bill & Melinda Gates Foundation)
ID : OPP1159947
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2023. The Author(s).
Références
WHO. World Malaria Report 2021 (WHO Press, 2021).
Sidjanski, S. P., Vanderberg, J. P. & Sinnis, P. Anopheles stephensi salivary glands bear receptors for region I of the circumsporozoite protein of Plasmodium falciparum. Mol. Biochem. Parasitol. 90, 33–41 (1997).
pubmed: 9497030
pmcid: 4011076
doi: 10.1016/S0166-6851(97)00124-2
Ménard, R. et al. Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature 385, 336–339 (1997).
pubmed: 9002517
doi: 10.1038/385336a0
Frevert, U. et al. Intravital observation of plasmodium berghei sporozoite infection of the liver. PLoS Biol. 3, e192 (2005).
pubmed: 15901208
pmcid: 1135295
doi: 10.1371/journal.pbio.0030192
Cerami, C. et al. The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of plasmodium falciparum sporozoites. Cell 70, 1021–1033 (1992).
pubmed: 1326407
doi: 10.1016/0092-8674(92)90251-7
Enea, V. et al. DNA cloning of plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science 225, 628–630 (1984).
pubmed: 6204384
doi: 10.1126/science.6204384
Dame, J. B. et al. Structure of the gene encoding the immunodominant surface antigen on the sporozoite of the human malaria parasite plasmodium falciparum. Science 225, 587–593 (1984).
doi: 10.1126/science.6204383
Casares, S., Brumeanu, T. D. & Richie, T. L. The RTS,S malaria vaccine. Vaccine 28, 4880–4894 (2010).
pubmed: 20553771
doi: 10.1016/j.vaccine.2010.05.033
Stoute, J. A. et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against plasmodium falciparum malaria. N. Engl. J. Med. 336, 86–91 (1997).
pubmed: 8988885
doi: 10.1056/NEJM199701093360202
Julien, J.-P. & Wardemann, H. Antibodies against Plasmodium falciparum malaria at the molecular level. Nat. Rev. Immunol. 19, 761–775 (2019).
pubmed: 31462718
doi: 10.1038/s41577-019-0209-5
Doud, M. B. et al. Unexpected fold in the circumsporozoite protein target of malaria vaccines. Proc. Natl Acad. Sci. USA. 109, 7817–7822 (2012).
pubmed: 22547819
pmcid: 3356675
doi: 10.1073/pnas.1205737109
Gandhi, K. et al. Variation in the circumsporozoite protein of plasmodium falciparum: vaccine development implications. PLoS ONE 9, e101783 (2014).
pubmed: 24992338
pmcid: 4081809
doi: 10.1371/journal.pone.0101783
Wahl, I. et al. Clonal evolution and TCR specificity of the human TFH cell response to Plasmodium falciparum CSP. Sci. Immunol. 7, 9644 (2022).
doi: 10.1126/sciimmunol.abm9644
Guttinger, M. et al. Human T cells recognize polymorphic and non-polymorphic regions of the Plasmodium falciparum circumsporozoite protein. EMBO J. 7, 2555–2558 (1988).
pubmed: 2461298
pmcid: 457127
doi: 10.1002/j.1460-2075.1988.tb03104.x
Good, M. F. et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: Immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc. Natl Acad. Sci. USA 85, 1199–1203 (1988).
pubmed: 2448793
pmcid: 279734
doi: 10.1073/pnas.85.4.1199
Moreno, A. et al. CD4+ T cell clones obtained from Plasmodium falciparum sporozoite-immunized volunteers recognize polymorphic sequences of the circumsporozoite protein. J. Immunol. 151, 489–499 (1993).
pubmed: 7686946
doi: 10.4049/jimmunol.151.1.489
Jalloh, A., Jalloh, M. & Matsuoka, H. T-cell epitope polymorphisms of the Plasmodium falciparum circumsporozoite protein among field isolates from Sierra Leone: Age-dependent haplotype distribution? Malar. J. 8, 120 (2009).
pubmed: 19500348
pmcid: 2698914
doi: 10.1186/1475-2875-8-120
Neafsey, D. E. et al. Genetic diversity and protective efficacy of the RTS,S/AS01 malaria vaccine. N. Engl. J. Med 373, 2025–2037 (2015).
pubmed: 26488565
pmcid: 4762279
doi: 10.1056/NEJMoa1505819
RTS, S. C. T. P. Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: Final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31–45 (2015).
doi: 10.1016/S0140-6736(15)60721-8
Mugo, R. M. et al. Seven-year kinetics of RTS, S/AS01-induced anti-CSP antibodies in young Kenyan children. Malar. J. 20, 452 (2021).
pubmed: 34856981
pmcid: 8641151
doi: 10.1186/s12936-021-03961-2
Datoo, M. S. et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet 397, 1809–1818 (2021).
pubmed: 33964223
pmcid: 8121760
doi: 10.1016/S0140-6736(21)00943-0
Datoo, M. S. et al. Efficacy and immunogenicity of R21/Matrix-M vaccine against clinical malaria after 2 years’ follow-up in children in Burkina Faso: a phase 1/2b randomised controlled trial. Lancet Infect. Dis. 22, 1728–1736 (2022).
pubmed: 36087586
doi: 10.1016/S1473-3099(22)00442-X
Birkett, A., Miller, R. S. & Soisson, L. A. The importance of exercising caution when comparing results from malaria vaccines administered on the EPI schedule and on a seasonal schedule. Am. J. Trop. Med. Hyg. 1, 1 (2022).
Murugan, R. et al. Clonal selection drives protective memory B cell responses in controlled human malaria infection. Sci. Immunol. 3, 8029 (2018).
doi: 10.1126/sciimmunol.aap8029
Thai, E. et al. A high-affinity antibody against the CSP N-terminal domain lacks Plasmodium falciparum inhibitory activity. J. Exp. Med. 217, e20200061 (2020).
pubmed: 32790871
pmcid: 7596816
doi: 10.1084/jem.20200061
Murugan, R. et al. Evolution of protective human antibodies against Plasmodium falciparum circumsporozoite protein repeat motifs. Nat. Med. 26, 1135–1145 (2020).
pubmed: 32451496
doi: 10.1038/s41591-020-0881-9
Triller, G. et al. Natural parasite exposure induces protective human anti-malarial antibodies. Immunity 47, 1197–1209 e10. (2017).
pubmed: 29195810
pmcid: 5738265
doi: 10.1016/j.immuni.2017.11.007
Wang, L. T. et al. A potent anti-malarial human monoclonal antibody targets circumsporozoite protein minor repeats and neutralizes sporozoites in the liver. Immunity 53, 733–744.e8. (2020).
pubmed: 32946741
pmcid: 7572793
doi: 10.1016/j.immuni.2020.08.014
Scally, S. W. et al. Rare human antibodies against the circumsporozoite protein C-terminal domain are ineffective against Pf sporozoites. J. Exp. Med. 215, 63–75 (2018).
pubmed: 29167197
pmcid: 5748854
doi: 10.1084/jem.20170869
Kisalu, N. K. et al. A human monoclonal antibody prevents malaria infection by targeting a new site of vulnerability on the parasite. Nat. Med. 24, 408–416 (2018).
pubmed: 29554083
pmcid: 5893371
doi: 10.1038/nm.4512
Tan, J. et al. A public antibody lineage that potently inhibits malaria infection through dual binding to the circumsporozoite protein. Nat. Med. 24, 401–407 (2018).
pubmed: 29554084
pmcid: 5893353
doi: 10.1038/nm.4513
Beutler, N. et al. A novel CSP C-Terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum. PLoS Pathog. 18, e1010409 (2022).
pubmed: 35344575
pmcid: 8989322
doi: 10.1371/journal.ppat.1010409
Espinosa, D. A. et al. Proteolytic cleavage of the Plasmodium falciparum circumsporozoite protein is a target of protective antibodies. J. Infect. Dis. 212, 1111–1119 (2015).
pubmed: 25762791
pmcid: 4559189
doi: 10.1093/infdis/jiv154
Chatterjee, D. et al. Avid binding by B cells to the Plasmodium circumsporozoite protein repeat suppresses responses to protective subdominant epitopes. Cell Rep. 35, 108996 (2021).
pubmed: 33852850
pmcid: 8052187
doi: 10.1016/j.celrep.2021.108996
Chaitra, M. G., Nayak, R. & Shaila, M. S. Modulation of immune responses in mice to recombinant antigens from PE and PPE families of proteins of Mycobacterium tuberculosis by the Ribi adjuvant. Vaccine 25, 7168–7176 (2007).
pubmed: 17709160
doi: 10.1016/j.vaccine.2007.07.026
Zavala, F., Cochrane, A. H., Nardin, E. H., Nussenzweig, R. S. & Nussenzweig, V. Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J. Exp. Med. 157, 1947–1957 (1983).
pubmed: 6189951
doi: 10.1084/jem.157.6.1947
Zavala, F. et al. Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science 228, 1436–1440 (1985).
pubmed: 2409595
doi: 10.1126/science.2409595
Langowski, M. D. et al. Restricted valency (NPNA)n repeats and junctional epitope-based circumsporozoite protein vaccines against Plasmodium falciparum. npj Vaccines 7, 1–11 (2022).
doi: 10.1038/s41541-022-00430-y
Langowski, M. D. et al. Optimization of a Plasmodium falciparum circumsporozoite protein repeat vaccine using the tobacco mosaic virus platform. Proc. Natl Acad. Sci. USA 117, 3114–3122 (2020).
pubmed: 31988134
pmcid: 7022184
doi: 10.1073/pnas.1911792117
Cockburn, I. A. & Seder, R. A. Malaria prevention: from immunological concepts to effective vaccines and protective antibodies. Nat. Immunol. 19, 1199–1211 (2018).
pubmed: 30333613
doi: 10.1038/s41590-018-0228-6
Alexander, J. et al. The optimization of helper T lymphocyte (HTL) function in vaccine development. Immunologic Res. 18, 79–92 (1998).
doi: 10.1007/BF02788751
Lee, E.-C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356–363 (2014).
pubmed: 24633243
doi: 10.1038/nbt.2825
Imkeller, K. et al. Antihomotypic affinity maturation improves human B cell responses against a repetitive epitope. Science 360, 1358–1362 (2018).
pubmed: 29880723
pmcid: 6420115
doi: 10.1126/science.aar5304
Houser, K. V. et al. Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial. Nat. Med. 28, 383–391 (2022).
pubmed: 35115706
doi: 10.1038/s41591-021-01660-8
Kanekiyo, M. et al. Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102–106 (2013).
pubmed: 23698367
pmcid: 8312026
doi: 10.1038/nature12202
Rivera-Hernandez, T. et al. Vaccine-induced th1-type response protects against invasive group a Streptococcus infection in the absence of opsonizing antibodies. MBio 11 (2020).
Rappuoli, R., Bottomley, M. J., D’Oro, U., Finco, O. & De Gregorio, E. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J. Exp. Med. 213, 469–481 (2016).
pubmed: 27022144
pmcid: 4821650
doi: 10.1084/jem.20151960
Sliepen, K. et al. Structure and immunogenicity of a stabilized HIV-1 envelope trimer based on a group-M consensus sequence. Nat. Commun. 10, 1–16 (2019).
doi: 10.1038/s41467-019-10262-5
Kanekiyo, M. et al. Rational design of an Epstein-Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090–1100 (2015).
pubmed: 26279189
pmcid: 4757492
doi: 10.1016/j.cell.2015.07.043
Swanson, K. A. et al. A respiratory syncytial virus (RSV) F protein nanoparticle vaccine focuses antibody responses to a conserved neutralization domain. Sci. Immunol. 5, 6466 (2020).
doi: 10.1126/sciimmunol.aba6466
Alexander, J. et al. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1, 751–761 (1994).
pubmed: 7895164
doi: 10.1016/S1074-7613(94)80017-0
Fraser, C. C. et al. Generation of a universal CD4 memory T cell recall peptide effective in humans, mice and non-human primates. Vaccine 32, 2896–2903 (2014).
pubmed: 24583006
doi: 10.1016/j.vaccine.2014.02.024
Kraft, J. C. et al. Antigen- and scaffold-specific antibody responses to protein nanoparticle immunogens. Cell Rep. Med. 3, 100780 (2022).
pubmed: 36206752
pmcid: 9589121
doi: 10.1016/j.xcrm.2022.100780
Read, B. J. et al. Mannose-binding lectin and complement mediate follicular localization and enhanced immunogenicity of diverse protein nanoparticle immunogens. Cell Rep. 38, 110217 (2022).
pubmed: 35021101
pmcid: 8805147
doi: 10.1016/j.celrep.2021.110217
Tokatlian, T. et al. Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers. Science 363, 649–654 (2019).
pubmed: 30573546
doi: 10.1126/science.aat9120
Harris, C. et al. Polymorphisms in Anopheles gambiae Immune Genes Associated with Natural Resistance to Plasmodium falciparum. PLoS Pathog. 6, e1001112 (2010).
pubmed: 20862317
pmcid: 2940751
doi: 10.1371/journal.ppat.1001112
Pompon, J. & Levashina, E. A. A new role of the mosquito complement-like cascade in male fertility in Anopheles gambiae. PLOS Biol. 13, e1002255 (2015).
pubmed: 26394016
pmcid: 4579081
doi: 10.1371/journal.pbio.1002255
Sattabongkot, J. et al. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax. Am. J. Trop. Med. Hyg. 74, 708–715 (2006).
pubmed: 16687667
doi: 10.4269/ajtmh.2006.74.708
Prado, M. et al. Long-term live imaging reveals cytosolic immune responses of host hepatocytes against plasmodium infection and parasite escape mechanisms. Autophagy 11, 1561–1579 (2015).
pubmed: 26208778
pmcid: 4590598
doi: 10.1080/15548627.2015.1067361
Lin, J. et al. A novel ‘gene insertion/marker out’ (GIMO) method for transgene expression and gene complementation in rodent malaria parasites. PLoS One 6, e29289 (2011).
pubmed: 22216235
pmcid: 3246482
doi: 10.1371/journal.pone.0029289
Janse, C. J., Ramesar, J. & Waters, A. P. High-efficiency transfection and drug selection of genetically transformed blood stages of the rodent malaria parasite Plasmodium berghei. Nat. Protoc. 1, 346–356 (2006).
pubmed: 17406255
doi: 10.1038/nprot.2006.53
Salman, A. M. et al. In Methods in Molecular Biology 1325, 257-286 (Humana Press Inc., 2015).
R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing 11 (R Core Team). https://www.r-project.org .